Guggenheim Starts Coverage on Sagimet Biosciences with Buy Rating
Guggenheim analyst gives Sagimet Biosciences a Buy rating with $27 target, citing promising results for its FASN inhibitor in MASH and acne.
/ 1659 items
#XY↓
FDA Grants Breakthrough Status to Zovegalisib for Advanced Breast Cancer
Relay Therapeutics' (RLAY) zovegalisib receives FDA Breakthrough Therapy designation for treating PIK3CA-mutant HR+/HER2- advanced breast cancer after CDK4/6 inhibitor treatment.
Pfizer Q4 2025: Strong Performance Despite COVID Decline
Pfizer beats Q4 estimates with $17.6B revenue as legacy drugs offset COVID sales drop. Obesity drug shows 12.3% weight loss. 2026 guidance reaffirmed.
Clear Street Starts Coverage on Caribou Biosciences with Buy Rating
Clear Street initiates coverage of Caribou Biosciences with a Buy rating and a $13 price target, highlighting strong CAR-T pipeline potential.
Acadia Pharmaceuticals Faces EU Setback for Rett Syndrome Drug Trofinetide
Acadia Pharmaceuticals (ACAD) receives negative CHMP vote for trofinetide EU approval despite 1,000+ patients using treatment globally. Company plans re-examination request.
Arbutus vs. Moderna Patent Case Heads to Jury Trial
Arbutus Biopharma stock rises 5% as judge orders jury trial in patent dispute over mRNA vaccine technology with Moderna, with trial set for March.